Medtronic plc, the global leader in medical technology, today announced its participation in the upcoming 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Berlin on Feb. 22-25, 2023. During the conference, Medtronic will be sharing out highly anticipated 12-month results from the Advanced Hybrid Closed Loop Study in Adult Population with Type 1 Diabetes (ADAPT), for which 6-month data was previously published by The Lancet Diabetes & Endocrinology.

Medtronic will also showcase new data that demonstrates how current technologies, like the MiniMed™ 780G system, and future technologies that will integrate Klue, a wearable device app and automated insulin delivery (AID) system that dispenses a meal bolus dose based on the user’s hand gestures, simplify mealtimes for those living with type 1 diabetes. This will include an industry symposium and workshop to demonstrate the advanced capabilities of the MiniMed™ 780G system, including its ability to handle meal management in real-world scenarios.

The MiniMed™ 780G system is the latest system from Medtronic and is currently available in more than 90 countries¹. It is under FDA review now in the United States.

Scientific Presentations

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing throughout the conference.

MiniMed™ 780G Data Presentations

• “12-month results of the ADAPT randomized controlled trial: Advanced hybrid closed-loop therapy versus conventional treatment in adults with type 1 diabetes” – oral presentation by Ohad Cohen, M.D., senior global medical affairs director, Medtronic Diabetes, on Friday, Feb. 24 at 2:24 a.m. CT (9:24 CET)
• “Cost-effectiveness analysis of the MiniMed™ 780G system versus multiple daily injections with intermittently scanned continuous glucose monitoring in individuals with type 1 diabetes across Europe” – e-poster presentation (#EP088) by Johan Jendle, M.D., Ph.D., professor at the faculty of Medical Sciences, director of the Research Center of Diabetes, Endocrinology and Metabolism, Örebro University, Sweden
• “The significance of coefficient of variation as a measure of hypoglycemia risk and time in range in real-world users of the MiniMed™ 780G system” – e-poster presentation (#EP406) by Javier Castañeda, senior manager, statistics, Medtronic Diabetes
• “Improved glycemic outcomes with increasing automation: A real-world analysis of patients transitioning from earlier MiniMed™ systems to the MiniMed™ 780G system” – e-poster presentation (#EP084) by Bruno Grassi, Ph.D., assistant professor at the School of Medicine, Department of Nutrition, Diabetes and Metabolism, Pontificia Universidad Católica de Chile, Santiago
• “Glycemic control with advanced hybrid closed-loop (AHCL) technology in a developing country: Results from 219 patients with diabetes in India” – e-poster presentation (#EP097) by V. Mohan, M.D., Madras Diabetes Research Foundation, Chennai, India
• “Glycemic outcomes of real-world MiniMed™ 780G system users from Latin America” – e-poster presentation (#EP065) by Matias Castro, principal medical liaison specialist, Medtronic Diabetes

Klue Presentations

• “An automated insulin delivery (AID) system with automatic meal bolus based on a hand-gesturing algorithm” – oral presentation by Anirban Roy, Ph.D., distinguished scientist, Bakken fellow, technical fellow, Medtronic Diabetes, on Thursday, Feb. 23 at 6:32 a.m. CT (13:32 CET)

Medtronic Sponsored Events

The following symposia will feature discussions with Medtronic and independent speakers. Of note, the symposium on Friday titled, ““Meal management – the final frontier for closed-loop insulin therapy in type 1 diabetes” will explore how closed-loop insulin therapy with simplified meal announcement capabilities can allow users to go beyond carb counting and focus back on general nutrition. The symposium will include real-world evidence that demonstrates the burden of carb counting and how to handle insulin-to-carb ratios. Details are as follows:

• “CGM alone is not enough – transforming MDI therapy with the Smart MDI system” chaired by Ohad Cohen, M.D. with speakers Madison Smith Ph.D., R.N., CDCES, R&D clinical product manager, Medtronic Diabetes, and Peter Moawad, senior product manager, Medtronic Diabetes, on Wednesday, Feb. 22, 7:30-9 a.m. CT (14:30-16 CET).
• “Simplifying meal management with the MiniMed™ 780G system” chaired by Ohad Cohen, M.D., on Thursday, Feb. 23, 6-7:30 a.m. CT (13-14:30 CET). Panelists and speakers to include Maya Laron Hirsh, head dietitian of diabetes and metabolism, Sheba Medical Center; Heather Lackey, director of global medical education, Medtronic Diabetes; and Francesca Gulotta, clinical research and diabetes specialist, Medtronic EMEA.
• “Meal management – the final frontier for closed-loop insulin therapy in type 1 diabetes” chaired by Ohad Cohen, M.D., and Jens Kröger, M.D., Centre for Diabetology, Hamburg Bergedorf, on Friday, Feb. 24, 3:30-5 a.m. CT (10:30-12 CET). Panelists and speakers to include Amir Tirosh, M.D., Ph.D., director, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ohad Cohen, M.D., Kirsten Nørgaard, M.D., DMsc, chief physician, Steno Diabetes Center Copenhagen, and David Dunleavy, Vice President, Portfolio Management, Medtronic Diabetes.

About the Diabetes Business at Medtronic (www.medtronicdiabetes.com) 
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes so people living with diabetes can enjoy greater freedom and better health. 

¹ MiniMed 780G System and Guardian™ 4 sensors are not commercially available or approved in the U.S.

For more information, contact:
Kendra Cassillo
Public Relations
+1-818-576-5611

Ryan Weispfenning
Investor Relations
+1-763-505-4626